Literature DB >> 30929159

MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.

Yang Liu1, Juan Tan1, Shuangyan Ou2, Jun Chen3, Limin Chen4.   

Abstract

MicroRNAs are involved in each stage of tumor development. Activation of the hepatocyte growth factor (HGF)/c-Met axis facilitates the proliferation and migration of cancer cells, and the HGF/c-MET pathway provides potential targets for anticancer treatment. However, the interaction between HGF and miRNAs in hepatocellular carcinoma (HCC) remains unknown. Previous studies have shown that miR-101 is downregulated in various types of cancer and acts as a tumor suppressor, but the role of miR-101 in HCC has not yet been well defined. Here, we show that HGF is upregulated while microRNA-101-3p is significantly downregulated in the tumor tissues of HCC. By combining bioinformatics analysis and luciferase reporter assays, we demonstrated that HGF is a direct target of miR-101. In vitro experiments indicated that miR-101 inhibits the migration and proliferation of HCC cells by targeting the HGF/c-MET axis, and in vivo studies showed that overexpressed miR-101 dramatically suppresses tumor growth. Therefore, the present study identifies miR-101 as a negative regulator of HGF/c-MET and suggests that miRNAs can be used as targeted drugs for the clinical treatment of HCC.

Entities:  

Keywords:  HGF; Hepatocellular carcinoma; c-MET; miR-101

Mesh:

Substances:

Year:  2019        PMID: 30929159     DOI: 10.1007/s10637-019-00766-8

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  39 in total

1.  Effect of epithelial cells derived from periodontal ligament on osteoblast-like cells in a Transwell membrane coculture system.

Authors:  Daisuke Noro; Yoshihito Kurashige; Kai Shudo; Ayumi Takahashi; Yoshihiro Abiko; Masato Saitoh
Journal:  Arch Oral Biol       Date:  2015-02-28       Impact factor: 2.633

2.  miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2.

Authors:  Jun-Jie Zhang; Chen-Yu Wang; Long Hua; Kun-Hou Yao; Jiang-Tao Chen; Jun-Hong Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Authors:  Yun Xie; Qinwei Yao; Azeem Mehmood Butt; Jia Guo; Zhou Tian; Xuli Bao; Hongxia Li; Qinghua Meng; Jun Lu
Journal:  Cancer Biol Ther       Date:  2014-06-27       Impact factor: 4.742

4.  Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway.

Authors:  Xiaoning Feng; Jingjin Jiang; Shaohua Shi; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  Int J Oncol       Date:  2016-11-02       Impact factor: 5.650

5.  c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma.

Authors:  M Tokunou; T Niki; K Eguchi; S Iba; H Tsuda; T Yamada; Y Matsuno; H Kondo; Y Saitoh; H Imamura; S Hirohashi
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 6.  Targeting the hepatocyte growth factor/Met pathway in cancer.

Authors:  Dinuka M De Silva; Arpita Roy; Takashi Kato; Fabiola Cecchi; Young H Lee; Kunio Matsumoto; Donald P Bottaro
Journal:  Biochem Soc Trans       Date:  2017-07-03       Impact factor: 5.407

Review 7.  c-Met as a Target for Personalized Therapy.

Authors:  Ingrid Garajová; Elisa Giovannetti; Guido Biasco; Godefridus J Peters
Journal:  Transl Oncogenomics       Date:  2015-11-23

8.  miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1).

Authors:  Qiao Zhu; Li Gong; Jun Wang; Qian Tu; Li Yao; Jia-Rui Zhang; Xiu-Juan Han; Shao-Jun Zhu; Shu-Mei Wang; Yan-Hong Li; Wei Zhang
Journal:  BMC Cancer       Date:  2016-10-18       Impact factor: 4.430

9.  MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α.

Authors:  Shuo Chen; Kai-Xuan Sun; Bo-Liang Liu; Zhi-Hong Zong; Yang Zhao
Journal:  Mol Cancer       Date:  2016-02-02       Impact factor: 27.401

Review 10.  Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).

Authors:  Irene Moya-Horno; Santiago Viteri; Niki Karachaliou; Rafael Rosell
Journal:  Ther Adv Med Oncol       Date:  2018-01-09       Impact factor: 8.168

View more
  9 in total

1.  Silencing CircEIF3I/miR-526b-5p Axis Epigenetically Targets HGF/c-Met Signal to Hinder the Malignant Growth, Metastasis and Angiogenesis of Hepatocellular Carcinoma.

Authors:  Yang Liu; Xia Xiao; Jingying Wang; Yitong Wang; Yanhui Yu
Journal:  Biochem Genet       Date:  2022-06-20       Impact factor: 1.890

2.  Identification of P-Rex1 in the Regulation of Liver Cancer Cell Proliferation and Migration via HGF/c-Met/Akt Pathway.

Authors:  Wancheng Qiu; Yanhua Chang; Jing Liu; Xu Yang; Yan Yu; Jiajia Li; Qing Liang; Guangchun Sun
Journal:  Onco Targets Ther       Date:  2020-09-24       Impact factor: 4.147

3.  mi-IsoNet: systems-scale microRNA landscape reveals rampant isoform-mediated gain of target interaction diversity and signaling specificity.

Authors:  Li Guo; Yongsheng Li; Kara M Cirillo; Robert A Marick; Zhe Su; Xing Yin; Xu Hua; Gordon B Mills; Nidhi Sahni; S Stephen Yi
Journal:  Brief Bioinform       Date:  2021-09-02       Impact factor: 11.622

4.  Glycogen Phosphorylase B Is Regulated by miR101-3p and Promotes Hepatocellular Carcinoma Tumorigenesis.

Authors:  Guangying Cui; Huifen Wang; Wenli Liu; Jiyuan Xing; Wengang Song; Zhaohai Zeng; Liwen Liu; Haiyu Wang; Xuemei Wang; Hong Luo; Xiaoyang Leng; Shen Shen
Journal:  Front Cell Dev Biol       Date:  2020-11-25

Review 5.  Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.

Authors:  Mohamed H Yousef; Hassan A N El-Fawal; Anwar Abdelnaser
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

Review 6.  Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk.

Authors:  Khadijeh Barzaman; Rana Vafaei; Mitra Samadi; Mohammad Hossein Kazemi; Aysooda Hosseinzadeh; Parnaz Merikhian; Shima Moradi-Kalbolandi; Mohammad Reza Eisavand; Houra Dinvari; Leila Farahmand
Journal:  Cancer Cell Int       Date:  2022-08-19       Impact factor: 6.429

Review 7.  Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy.

Authors:  Xin Liu; Ranran Sun; Jianan Chen; Liwen Liu; Xichun Cui; Shen Shen; Guangying Cui; Zhigang Ren; Zujiang Yu
Journal:  Front Cell Dev Biol       Date:  2020-01-31

8.  FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma.

Authors:  Yan Wang; Mengjing Sun; Jibin Liu; Ying Liu; Chunyi Jiang; Huijun Zhu; Wei Wang; Yao Wang
Journal:  Oncol Lett       Date:  2019-12-04       Impact factor: 2.967

9.  A microRNA delivery carrier for hepatic carcinoma therapy using layer-by-layer self-assembled mesenchymal stem cells.

Authors:  Chunmin Li; Xin Li; Fengsheng Li; Dawei Wang; Jin Wang; Tao Yan; Bo Sun; Hualiang Ren
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.